Full Text Journal Articles by
Author Rachel Roberts Thomson

Advertisement

Find full text journal articles








Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.

B Mark Smithers, Robyn P M Saw, David E Gyorki, Richard C W Martin, Victoria Atkinson, Andrew Haydon, Rachel Roberts-Thomson, John F Thompson,

Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care pathways for patients with melanoma. Accurate staging is critical to ensure a ... Read more >>

ANZ J Surg (ANZ journal of surgery)
[2021, 91 Suppl 2:3-13]

Cited: 0 times

View full text PDF listing >>



Recent advancements in melanoma management.

Tharani Krishnan, Alexander M Menzies, Rachel Roberts-Thomson,

The treatment options for patients with melanoma have expanded significantly over the past decade. In particular, the use of targeted therapy and immunotherapy has dramatically transformed the outlook for patients with advanced disease. These treatments are now being utilised as adjuvant therapy for patients with earlier stage melanoma after surgical ... Read more >>

Intern Med J (Internal medicine journal)
[2021, 51(3):327-333]

Cited: 1 time

View full text PDF listing >>



Advertisement

Applying adjuvant therapy for melanoma into clinical practice.

Tharani Krishnan, Alexander M Menzies, Rachel Roberts-Thomson,

Expert Rev Anticancer Ther (Expert review of anticancer therapy)
[2021, 21(2):129-133]

Cited: 0 times

View full text PDF listing >>



A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy.

Tharani Krishnan, Yoko Tomita, Rachel Roberts-Thomson,

<h4>Aim</h4>To investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy.<h4>Materials & methods</h4>We evaluated the association between eosinophilia and treatment response and toxicity in a retrospective cohort of patients receiving cancer immunotherapy.<h4>Results</h4>The study involved 146 patients. Eosinophilia developed in 22%. Patients who developed eosinophilia were more likely to ... Read more >>

Future Sci OA (Future science OA)
[2020, 6(10):FSO608]

Cited: 0 times

View full text PDF listing >>



Duration of immunotherapy - should we continue ad infinitum?

Annabel Smith, Gohar Shaghayegh, Alexander M Menzies, Rachel Roberts-Thomson,

The optimal duration of immunotherapy treatment for cancer patients is unknown. As the survival data from early immunotherapy trials mature we are beginning to appreciate how durable responses can be post-discontinuation. The purpose of this brief communication is to comment on treatment duration of immunotherapy in patients with melanoma and ... Read more >>

Intern Med J (Internal medicine journal)
[2020, 50(7):865-868]

Cited: 0 times

View full text PDF listing >>



Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current Evidence.

Tiffany Foo, Gonzalo Tapia Rico, Rachel Roberts-Thomson,

Despite the increasing incidence of metastatic melanoma in the older population, there is relatively limited specific data surrounding the use of immunotherapy for the treatment of advanced melanoma for patients above the age of 65 years. To date, there has not been a prospective trial done to evaluate the safety and ... Read more >>

Drugs Aging (Drugs & aging)
[2020, 37(6):411-423]

Cited: 0 times

View full text PDF listing >>



Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Ines Pires da Silva, Isabella C Glitza, Lauren E Haydu, Romany Johnpulle, Patricia D Banks, George D Grass, Simone M A Goldinger, Jessica L Smith, Ashlyn S Everett, Peter Koelblinger, Rachel Roberts-Thomson, Michael Millward, Victoria G Atkinson, Alexander Guminski, Rony Kapoor, Robert M Conry, Matteo S Carlino, Wei Wang, Mark J Shackleton, Zeynep Eroglu, Serigne Lo, Angela M Hong, Georgina V Long, Douglas B Johnson, Alexander M Menzies,

<h4>Background</h4>Brain radiotherapy is used in the management of melanoma brain metastases (MBM) and can result in radionecrosis. Anti-PD-1 is active in the brain and may increase the risk of radionecrosis when combined with radiotherapy. We studied the incidence, associated factors and management of radionecrosis in longer-term survivors with MBM treated ... Read more >>

Pigment Cell Melanoma Res (Pigment cell & melanoma research)
[2019, 32(4):553-563]

Cited: 7 times

View full text PDF listing >>



Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf, ,

BACKGROUND:Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma. METHODS:BRIM8 was a phase 3, international, double-blind, randomised, placebo-controlled study that enrolled 498 adults (aged ≥18 years) with ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2018, 19(4):510-520]

Cited: 37 times

View full text PDF listing >>



Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

Victoria Atkinson, Georgina V Long, Alexander M Menzies, Grant McArthur, Matteo S Carlino, Michael Millward, Rachel Roberts-Thomson, Benjamin Brady, Richard Kefford, Andrew Haydon, Jonathan Cebon,

BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy with BRAF and MEK inhibition improves response rate, progression free survival and overall survival compared with single agent BRAF inhibition, and ... Read more >>

Asia Pac J Clin Oncol (Asia-Pacific journal of clinical oncology)
[2016, 12 Suppl 7:5-12]

Cited: 5 times

View full text PDF listing >>



Carboplatin dosing in ovarian cancer: problems and pitfalls.

Ian M Collins, Rachel Roberts-Thomson, David Faulkner, Danny Rischin, Michael Friedlander, Linda Mileshkin,

<h4>Objective</h4>Carboplatin is one of the most effective chemotherapeutic drugs for the treatment of ovarian cancer. It has simple pharmacokinetics and a predictable toxicity profile. The dose can be calculated effectively based on a patient's renal function as defined by the glomerular filtration rate (GFR). The measurement of the GFR is ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2011, 21(7):1213-1218]

Cited: 9 times

View full text PDF listing >>





Advertisement

Disclaimer
1.2501 s